DAWN — Day One Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.22bn
- $1.78bn
- $158.18m
Day One Biopharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Day One Biopharmaceuticals Q2 OJEMDA revenue rises
Day One Biopharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Day One Appoints Michael Vasconcelles As Head Of Research And Development
Day One Biopharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Day One Biopharmaceuticals Q1 EPS USD -0.35 Vs. IBES Estimate USD -0.44
U.S. RESEARCH ROUNDUP-BXP, Hubspot, Qualcomm
Brief: Ipsen And Day One Enter Into Exclusive Ex-U.S. Licensing Agreement To Commercialize Tovorafenib For The Most Common Childhood Brain Tumor
Brief: Ipsen And Day One Enter Into Exclusive Ex-U.S. Licensing Agreement To Commercialize Tovorafenib For The Most Common Childhood Brain Tumor
Brief: Day One Biopharmaceuticals Expands Pipeline With Antibody Drug Conjugate Candidate For Adult And Pediatric Cancers
Day One Biopharma gains on FDA's accelerated nod for brain tumor treatment
Brief: FDA Grants Accelerated Approval To Tovorafenib For Patient With Relapsed Or Refractory Braf-Altered Pediatric Low-Grade Glioma
Brief: Day One Biopharmaceuticals Increased Board Size To Ten Directors
U.S. RESEARCH ROUNDUP- Arista Networks, Credit Acceptance, Tractor Supply
U.S. STOCKS ON THE MOVE-SeaStar, SJW Group, Pinterest
U.S. STOCKS ON THE MOVE-Crypto, Miromatrix Medical, US banks
Day One Biopharma up after FDA accepts marketing application of brain tumor therapy
Brief: Day One Announces FDA Acceptance Of NDA And Priority Review For Tovorafenib
Brief: Day One Provides Updated Firefly-1 Data For Tovorafenib